2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights.
Saved in:
| Title: | 2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights. |
|---|---|
| Authors: | Elbadawi MM; Department of Chemistry, Graduate School of Science, Hiroshima University, Hiroshima, Japan.; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt., Eldehna WM; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt., Abd El-Hafeez AA; Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA., Somaa WR; Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt., Albohy A; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The British University in Egypt (BUE), Cairo, Egypt., Al-Rashood ST; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Agama KK; Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA., Elkaeed EB; Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia., Ghosh P; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.; Department of Medicine, University of California San Diego, La Jolla, CA, USA.; Moores Comprehensive Cancer Center, University of California San Diego, La Jolla, CA, USA.; Veterans Affairs Medical Center, La Jolla, CA, USA., Pommier Y; Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA., Abe M; Department of Chemistry, Graduate School of Science, Hiroshima University, Hiroshima, Japan. |
| Source: | Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 349-372. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101150203 Publication Model: Print Cited Medium: Internet ISSN: 1475-6374 (Electronic) Linking ISSN: 14756366 NLM ISO Abbreviation: J Enzyme Inhib Med Chem Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 34923887 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Elbadawi+MM%22">Elbadawi MM</searchLink>; Department of Chemistry, Graduate School of Science, Hiroshima University, Hiroshima, Japan.; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.<br /><searchLink fieldCode="AU" term="%22Eldehna+WM%22">Eldehna WM</searchLink>; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.<br /><searchLink fieldCode="AU" term="%22Abd+El-Hafeez+AA%22">Abd El-Hafeez AA</searchLink>; Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.<br /><searchLink fieldCode="AU" term="%22Somaa+WR%22">Somaa WR</searchLink>; Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.<br /><searchLink fieldCode="AU" term="%22Albohy+A%22">Albohy A</searchLink>; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The British University in Egypt (BUE), Cairo, Egypt.<br /><searchLink fieldCode="AU" term="%22Al-Rashood+ST%22">Al-Rashood ST</searchLink>; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Agama+KK%22">Agama KK</searchLink>; Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Elkaeed+EB%22">Elkaeed EB</searchLink>; Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia.<br /><searchLink fieldCode="AU" term="%22Ghosh+P%22">Ghosh P</searchLink>; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.; Department of Medicine, University of California San Diego, La Jolla, CA, USA.; Moores Comprehensive Cancer Center, University of California San Diego, La Jolla, CA, USA.; Veterans Affairs Medical Center, La Jolla, CA, USA.<br /><searchLink fieldCode="AU" term="%22Pommier+Y%22">Pommier Y</searchLink>; Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Abe+M%22">Abe M</searchLink>; Department of Chemistry, Graduate School of Science, Hiroshima University, Hiroshima, Japan. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101150203%22">Journal of enzyme inhibition and medicinal chemistry</searchLink> [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 349-372. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101150203 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1475-6374 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214756366%22">14756366 </searchLink><i>NLM ISO Abbreviation: </i>J Enzyme Inhib Med Chem <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34923887 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1080/14756366.2021.2015344 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 349 Titles: – TitleFull: 2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Elbadawi MM – PersonEntity: Name: NameFull: Eldehna WM – PersonEntity: Name: NameFull: Abd El-Hafeez AA – PersonEntity: Name: NameFull: Somaa WR – PersonEntity: Name: NameFull: Albohy A – PersonEntity: Name: NameFull: Al-Rashood ST – PersonEntity: Name: NameFull: Agama KK – PersonEntity: Name: NameFull: Elkaeed EB – PersonEntity: Name: NameFull: Ghosh P – PersonEntity: Name: NameFull: Pommier Y – PersonEntity: Name: NameFull: Abe M IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 12 Text: 2022 Dec Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1475-6374 Numbering: – Type: volume Value: 37 – Type: issue Value: 1 Titles: – TitleFull: Journal of enzyme inhibition and medicinal chemistry Type: main |
| ResultId | 1 |
